ERBB2 and breast cancer: Despite these limitations, long-term outcomes of TUXEDO-1 support the hypothesis that despite its large molecular size, T-DXd yields clinically relevant activity in active BM from HER2-positive BC and allows for prolonged intra- and extracranial disease control with acceptable tolerability and maintained QoL function.